My watch list
my.bionity.com  
Login  

639 Current news from israel

rss
matching the following criteria

Small signaling molecule gives green light for cell division

12-May-2015

Generating offspring is the evolutionary goal of all living organisms. The multiplication of individual cells is coordinated by the cell cycle. For the discovery of how this process is regulated in eukaryotes the Noble Prize was awarded in 2001. The team of Prof. Urs Jenal at the Biozentrum of ...

more

Light in sight

Restoring vision to blind mice

11-May-2015

Scientists from the Universities of Bern in Switzerland and Göttingen in Germany have succeeded in restoring vision to blind mice. They've developed a molecular light switch as a potential therapy for acquired blindness. Hereditary blindness caused by a progressive degeneration of the ...

more

Cotton fibres instead of carbon nanotubes

11-May-2015

Plant-based cellulose nanofibres do not pose a short-term health risk, especially short fibres, shows a study conducted in the context of National Research Programme "Opportunities and Risks of Nanomaterials" (NRP 64). But lung cells are less efficient in eliminating longer fibres. Similar to ...

more

Siegfried acquires significant segments of BASF’s pharmaceutical supply business

08-May-2015

The Siegfried Group signed an agreement with the German company BASF with the aim of acquiring significant segments of BASF’s pharmaceutical supply business and connected chemical-pharmaceutical production units in Germany, France and Switzerland. Siegfried expects the transaction to be concluded ...

more

Mymetics-Led Consortium Awarded €8.4 Million for Development of Thermo Stable and Cold-Chain Independent Vaccines

24-Apr-2015

Mymetics Corporation announced that its subsidiary Mymetics BV in the Netherlands is leading a consortium that has been selected to receive project grants with a total value of €8.4 million. A total of €5.3 million is funded as part of Horizon 2020, the European Union research and innovation ...

more

Santhera's Positive Phase III Trial (DELOS) in Patients with Duchenne Muscular Dystrophy

24-Apr-2015

Santhera Pharmaceuticals announced that the full results of the double-blind placebo-controlled Phase III trial (DELOS) demonstrating efficacy and safety of Raxone®/Catena® (INN: idebenone) in patients with DMD have been published in The Lancet. The results of the DELOS trial demonstrated that ...

more

Evidence grows that melanoma drugs benefit some lung cancer patients

Many patients with BRAF-mutant cancers benefit from treatment with BRAF inhibitors, European researchers report at ELCC

22-Apr-2015

A subset of lung cancer patients can derive important clinical benefits from drugs that are more commonly used to treat melanoma, the authors of a new academic clinical trial in Europe have reported at the European Lung Cancer Conference (ELCC) in Geneva, Switzerland.Dr. Oliver Gautschi, a ...

more

DNA blood test detects lung cancer mutations

Circulating tumour DNA in blood a valid option for EGFR testing in patients who do not have accessible tumour tissue, study shows

21-Apr-2015

Cancer DNA circulating in the bloodstream of lung cancer patients can provide doctors with vital mutation information that can help optimise treatment when tumour tissue is not available, an international group of researchers has reported at the European Lung Cancer Conference (ELCC) in Geneva, ...

more

Smokers underestimate risks of a few cigarettes

Survey shows that many live in ‘denial’ of the real risks of smoking even a small number of cigarettes a day

20-Apr-2015

Many people still dangerously underestimate the health risks associated with smoking even a few cigarettes a day, despite decades of public health campaigning, French researchers have reported at the European Lung Cancer Conference (ELCC) in Geneva, Switzerland. The results demonstrate powerfully ...

more

Sobi receives orphan drug designation for Elocta in Switzerland

17-Apr-2015

Swedish Orphan Biovitrum AB has received orphan drug designation in Switzerland for its long acting haemophilia drug candidate Elocta (rFVIIIFc) developed for the treatment of haemophilia A. An orphan drug designation is to encourage the development of medicines for rare diseases and provides ...

more

Page 1 From 64
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE